PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION Russian patent published in 2022 - IPC A61K39/395 A61P35/00 C07K16/28 

FIELD: biotechnology.

SUBSTANCE: group of inventions is described, including a pharmaceutical composition for the treatment of PD-L1-mediated disease or condition, a method for producing a pharmaceutical composition, the use of a pharmaceutical composition in the manufacture of a drug for the treatment of PD-L1-mediated disease or condition, and a method for the treatment of PD-L1-mediated disease or condition. In one of embodiments, the pharmaceutical composition contains 30-80 mg/ml of an antibody to PD-L1 or its antigen-binding fragment, 5-50 mM of a succinate buffer, 30-90 mg/ml of saccharide, while saccharide is trehalose or sucrose, and 0.01-1.0 mg/ml of polysorbate 80, and the antibody to PD-L1 contains HCDR1, HCDR2 and HCDR3 that are represented under SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively, and LCDR1, LCDR2 and LCDR3 that are represented under SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12, respectively.

EFFECT: invention expands the arsenal of means for the treatment of PD-L1-mediated diseases or conditions.

16 cl, 3 dwg, 7 tbl, 6 ex